Guidance for the Conduct and Reporting of Clinical Trials of Breast Milk Substitutes.
Journal
JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
pubmed:
12
5
2020
medline:
26
3
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Breast milk substitutes (BMS) are important nutritional products evaluated in clinical trials. Concerns have been raised about the risk of bias in BMS trials, the reliability of claims that arise from such trials, and the potential for BMS trials to undermine breastfeeding in trial participants. Existing clinical trial guidance does not fully address issues specific to BMS trials. To establish new methodological criteria to guide the design, conduct, analysis, and reporting of BMS trials and to support clinical trialists designing and undertaking BMS trials, editors and peer reviewers assessing trial reports for publication, and regulators evaluating the safety, nutritional adequacy, and efficacy of BMS products. A modified Delphi method was conducted, involving 3 rounds of anonymous questionnaires and a face-to-face consensus meeting between January 1 and October 24, 2018. Participants were 23 experts in BMS trials, BMS regulation, trial methods, breastfeeding support, infant feeding research, and medical publishing, and were affiliated with institutions across Europe, North America, and Australasia. Guidance development was supported by an industry consultation, analysis of methodological issues in a sample of published BMS trials, and consultations with BMS trial participants and a research ethics committee. An initial 73 criteria, derived from the literature, were sent to the experts. The final consensus guidance contains 54 essential criteria and 4 recommended criteria. An 18-point checklist summarizes the criteria that are specific to BMS trials. Key themes emphasized in the guidance are research integrity and transparency of reporting, supporting breastfeeding in trial participants, accurate description of trial interventions, and use of valid and meaningful outcome measures. Implementation of this guidance should enhance the quality and validity of BMS trials, protect BMS trial participants, and better inform the infant nutrition community about BMS products.
Identifiants
pubmed: 32391870
pii: 2765822
doi: 10.1001/jamapediatrics.2020.0578
pmc: PMC7215627
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-881Références
Palliat Med. 2017 Sep;31(8):684-706
pubmed: 28190381
BMJ. 2016 Mar 08;352:i974
pubmed: 26956579
Nature. 2010 Sep 23;467(7314):401
pubmed: 20864982
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
JAMA Intern Med. 2016 Jan;176(1):13-4
pubmed: 26595855
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
Lancet. 2016 Jan 30;387(10017):475-90
pubmed: 26869575
Clin Pediatr (Phila). 2016 May;55(5):437-42
pubmed: 26054781
BMJ. 2018 Oct 3;363:k3654
pubmed: 30282703
Int Breastfeed J. 2014 Jan 16;9(1):2
pubmed: 24433303
J Adv Nurs. 2003 Feb;41(4):376-82
pubmed: 12581103
Lancet. 2016 Jan 30;387(10017):491-504
pubmed: 26869576
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
Lancet. 2014 Jan 11;383(9912):166-75
pubmed: 24411645
Cochrane Database Syst Rev. 2017 Feb 16;2:MR000033
pubmed: 28207928
J Pediatr. 2015 Mar;166(3):756-60
pubmed: 25491093
JAMA Pediatr. 2017 Feb 1;171(2):105-106
pubmed: 28027329
Trends Pharmacol Sci. 2013 Dec;34(12):645-7
pubmed: 24295825
JAMA. 2018 Jan 2;319(1):38-48
pubmed: 29297078
Trials. 2013 Mar 12;14:70
pubmed: 23497540